hsg logo white

FAQs

Valbenazine (valbenazine tosylate, NBI-98854) is a selective, orally active VMAT2 inhibitor developed by Neurocrine Biosciences, Inc. Valbenazine is being investigated for the treatment of chorea associated with HD. Valbenazine was approved by the United States Food and Drug Administration (FDA) in April 2017 for the treatment of adults with tardive dyskinesia (TD), under the trade name INGREZZA®.

Twenty-seven clinical studies with valbenazine have been completed to date: 16 Phase 1 studies in healthy subjects or special populations (for example, patients with impaired liver or kidney function); 7 Phase 2 or 3 studies in subjects with TD, and 4 Phase 1b or 2 studies in subjects with Tourette syndrome (TS; 1 in adults; 2 in children and adolescents; and 1 in children, adolescents, and adults).

Most commonly-reported side effects with valbenazine administration include drowsiness, tiredness and sedation (feeling calm, relaxed or sleepy).

Valbenazine is being evaluated as a symptomatic treatment of involuntary movement (chorea) associated with HD. Valbenazine is not an approved treatment or cure for HD.

Valbenazine was approved by the United States Food and Drug Administration (FDA) in April 2017 for the treatment of adults with tardive dyskinesia (TD), under the trade name INGREZZA®.